How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

297 results for

adhd Bupropion

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Evidence-based Guidelines for Treating Bipolar Disorder

and the challenge is to enhance its recogni- tion. The approach to diagnosis in children is poorly operational- ized: diagnostic instruments are available that could aid clinical practice (II). The so-called broad bipolar phenotype of childhood has been replaced by a new diagnosis in DSM-5: disruptive mood dys- regulation disorder (DMDD). This is not a bipolar diagnosis and is likely to be rather common in comparison with bipolar disor- der, which is rare in prepubescent children (I). Following puberty (...) Evidence-based Guidelines for Treating Bipolar Disorder Journal of Psychopharmacology 2016, Vol. 30(6) 495 –553 © The Author(s) 2016 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0269881116636545 jop.sagepub.com Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology GM Goodwin 1 , PM Haddad 2 , IN Ferrier 3 , JK Aronson 4 , TRH Barnes 5 , A Cipriani 1 , DR Coghill 6 , S

2016 British Association for Psychopharmacology

102. Evidence-based guidelines for treating bipolar disorder

and the challenge is to enhance its recogni- tion. The approach to diagnosis in children is poorly operational- ized: diagnostic instruments are available that could aid clinical practice (II). The so-called broad bipolar phenotype of childhood has been replaced by a new diagnosis in DSM-5: disruptive mood dys- regulation disorder (DMDD). This is not a bipolar diagnosis and is likely to be rather common in comparison with bipolar disor- der, which is rare in prepubescent children (I). Following puberty (...) Evidence-based guidelines for treating bipolar disorder Journal of Psychopharmacology 2016, Vol. 30(6) 495 –553 © The Author(s) 2016 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0269881116636545 jop.sagepub.com Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology GM Goodwin 1 , PM Haddad 2 , IN Ferrier 3 , JK Aronson 4 , TRH Barnes 5 , A Cipriani 1 , DR Coghill 6 , S

2016 British Association for Psychopharmacology

103. Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity

regimens. Current or prior (within prior 2 months) use of any medication, including those approved to treat obesity, that could impact the efficacy results of this study (eg, orlistat, lorcaserin, phentermine-topiramate, naltrexone-bupropion, liraglutide). Patients on a stable dose and regimen (for at least 2 months) of medication to treat attention deficit hyperactivity disorder (ADHD) may be enrolled in the study as long as they agree to remain on the same dose and regimen during the study. Prior (...) to enrollment. Diagnosis of schizophrenia, bipolar disorder, personality disorder or other Diagnostic and Statistical Manual of Mental Disorders fifth edition (DSM-V) disorders that the Investigator believes will interfere significantly with study compliance. Neurocognitive disorders affecting ability to consent will not be disqualifying as long as an appropriate guardian able to give consent has been appointed. In patients with no significant neurocognitive deficits: A PHQ-9 score of ≥15 and/or Any

2018 Clinical Trials

104. Effects of Metformin During Nicotine Withdrawal

diagnosis of bipolar disorder, eligible if: No psychotic features MADRS: total score less than 8 (past 4 weeks), suicidal item score less than1 (past 4 weeks) Y-MRS: total score less than 8 (past 4 weeks), irritability, speech content, disruptive or aggressive behavior items score less than 3 (past 4 weeks) No psychiatric hospitalization or Emergency Room visits for psychiatric issues in the past 6 months No aggressive or violent acts or behavior in the past 6 months Able to communicate fluently (...) following 24h of smoking abstinence [ Time Frame: Day 23 ] Composite score of computer-based neurocognitive tasks (N-back Working Memory Task, Stop Signal Task, Hopkins Verbal Learning Test - Revised [HVLT-R]) designed to test working memory and attention. Secondary Outcome Measures : Self-reported smoking behavior [ Time Frame: Days 7, 14, 21, and 23 ] Cigarettes smoked per day as reported on the Timeline Follow-Back (TLFB). Cigarettes smoked per day is assessed using a "past week" time reference

2018 Clinical Trials

105. Management of smoking in pregnant women

women. Nicotine Tob Res 2013;15:969–77. 40. Hemsing N, Greaves L, O’Leary R, Chan K, Okoli C. Partner support for smoking cessation during pregnancy: a systematic review. Nicotine Tob Res 2012;14:767–76.CLINICAL Management of smoking in pregnant women REPRINTED FROM AUSTRALIAN FAMILY PHYSICIAN VOL. 43, NO. 1–2, JANUARY– FEBRUARY 2014 51 65. Button TM, Thapar A, McGuffin P . Relationship between antisocial behaviour, attention-deficit hyperactivity disorder and maternal prenatal smoking. Br J (...) decrease 61 Nicotine dependence Double the risk 62 Respiratory Asthma, lower respiratory infection, decreased lung function 63 Cognition Impaired academic performance and cognitive abilities 64 Behaviour Conduct disorder, ADHD, antisocial behaviour 65 Psychiatric disorders Significant increase for most psychiatric disorders in early adulthood 66 OR = odds ratio; ns = not significant; HDL = high density lipoproteinManagement of smoking in pregnant women CLINICAL 48 REPRINTED FROM AUSTRALIAN FAMILY

2014 Clinical Practice Guidelines Portal

106. General practice management of type 2 diabetes 2014-15

for Excellence in Indigenous Tobacco Control (CEITC) (CEITC Quitting resources, www.ceitc.org.au/quitting-resources). In the absence of contraindications, smokers who have evidence of nicotine dependence should be offered pharmacotherapy if they are motivated to stop smoking. Choice of pharmacotherapy is based on clinical suitability and patient choice. There is a lack of safety data on the use of varenicline or bupropion in diabetes. However, if diabetes is well controlled with insulin or oral hypoglycaemic (...) medication, 150 mg once daily of bupropion can be prescribed. If the diabetes is poorly controlled, nicotine replacement therapy should be considered. 61General practice management of type 2 diabetes 33 6.5 Alcohol consumption Recommendations Reference Grade* People with diabetes can take alcohol in moderation as part of a healthy lifestyle but should aim to keep within the target consumption recommended for people without diabetes (64) SIGN, 2010 B *Refer to Appendix A for an explanation of the Grade

2014 Clinical Practice Guidelines Portal

107. Management of Obesity and Overweight

lifestyle intervention for weight loss should be offered to all obese patients and overweight patients with obesity-associated chronic health conditions. Comprehensive lifestyle intervention is the foundation of treatment for overweight and obesity and should include at least 12 contacts over a year of an intervention that combines dietary, physical activity and behavioral components. Diet and physical activity together must create an energy deficit of 500- 1000 kcal/day for effective weight loss (...) Recommendations 17 Screening and Assessment for Overweight and Obesity 20 Normal Weight Patients 22 Overweight Patients Without Obesity-Associated Condition(s) 23 Overweight Patients With Obesity-Associated Condition(s) 23 Obese Patients 25 Shared Decision-Making 26 General Treatment Principles 27 Behavioral and Lifestyle Approaches 31 Dietary Approaches 32 Physical Activity Approaches 34 Pharmacotherapy 36 Bariatric surgery 37 Future Research 40 Appendix A: Evidence Review Methodology 42 Formulating Evidence

2014 VA/DoD Clinical Practice Guidelines

108. Treatment and recommendations for homeless people with Opioid Use Disorders

withdrawal procedures or medication assisted treatment induction. ? Utilize tools such as motivational enhancement techniques and brief office-based counseling to help assess patients’ level of readiness for behavioral change. TREATMENT, MANAGEMENT ? Offer medication-assisted treatment to any patient with an opioid use disorder. ? Encourage use of nonpharmacologic interventions, whether patients are receiving medication-assisted treatment or not: harm reduction therapy, peer mentoring, peer support (...) the plan of care; implement strategies to minimize risk of diversion/ misuse (random drug tests, alternate day dosing, prescription monitoring program, directly observed therapy). Balance overall benefits of continuing MAT with potential harms. FOLLOW-UP ? Determine frequency of follow-up based on stability of the patient and his/her living situation and risk of diversion/ misuse/ abuse of medications used for treatment of opioid use disorders or other substances. ? At each visit, assess for behaviors

2014 National Health Care for the Homeless Council

109. Menopause Chapter 3: Clinical Issues

may be helpful for problems of sexual interest and arousal. Bupropion and PDE-5 inhibitors may have a role in the treatment of SSRI-induced sexual dysfunction. (Level II) There is some evidence to support the use of testosterone therapy in carefully selected postmenopausal women with female sexual interest/arousal disorder (previously known as hypoactive sexual desire disorder) and no other etiology for their sexual problem, although a formulation designed for women and long-term safety data (...) , although adverse effects and poor compliance may limit success. Nonhormonal agents used to manage AUB include nonsteroidal anti-inflammatory agents, tranexamic acid, and desmopressin for women with an underlying bleeding disorder. Hormonal options for managing AUB include low-dose oral contraceptives, cyclic oral progestogens, depot medroxyprogesterone acetate injections, the levonorgestrel-releasing intrauterine system, and gonadotropin-releasing hormone (GnRH) agonists. The use of GnRH agonists

2014 The North American Menopause Society

110. Severe Obesity in Children and Adolescents: Identification, Associated Health Risks, and Treatment Approaches Full Text available with Trip Pro

, current treatments are limited in effectiveness and lack widespread availability. Lifestyle modification/behavior-based treatment interventions in youth with severe obesity have demonstrated modest improvement in body mass index status, but participants have generally remained severely obese and often regained weight after the conclusion of the treatment programs. The role of medical management is minimal, because only 1 medication is currently approved for the treatment of obesity in adolescents (...) awareness of this serious and growing problem by summarizing the current literature in this area in terms of the epidemiology and trends, associated health risks (immediate and long-term), and challenges and shortcomings of currently available treatment options; and (3) highlight areas in need of future research. Innovative behavior-based treatment, minimally invasive procedures, and medications currently under development all need to be evaluated for their efficacy and safety in this group of patients

2013 American Heart Association

111. 2013 ACCF/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes and Coronary Artery Disease Full Text available with Trip Pro

of interest. These statements were reviewed by the ACCF/AHA Task Force on Clinical Data Standards, reported orally to all members of the writing panel at the first meeting, and updated as changes occur. In clinical care, caregivers communicate with each other through a common vocabulary. In an analogous fashion, the integrity of clinical research depends on firm adherence to prespecified procedures for patient enrollment and follow-up; these procedures are guaranteed through careful attention

2013 American Heart Association

112. Health Supervision in the Management of Children and Adolescents With IBD: NASPGHAN Recommendations

of urine creatinine, electrolytes, calcium, magnesium, uric acid, citrate, oxalate, volume, and pH should be obtained. Bone Health in Children With IBD Recent data underscore the need for physicians caring for children with IBD to pay particular attention to assessing and ensuring adequate vitamin D and calcium intake by their patients. Significant deficits in bone mass have been observed in 10% to 40% of children presenting with IBD, and these deficits appear to be more pronounced in patients with CD (...) ) and Crohn disease (CD), collectively referred to as in?ammatory bowel disease (IBD), are chronic in?ammatory disorders that can affect the gastrointestinal tract of children and adults. Like other autoimmune processes, the cause(s) of these disorders remain unknown but likely involves some interplay between genetic vulnerability and environ- mental factors. Children, in particular with UC or CD, can present to their primary care providers with similar symptoms, including abdominal pain, diarrhea, weight

2012 North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

113. Tobacco Treatment

. • Anticipate challenges, particularly during the first critical few weeks, i.e., nicotine withdrawal symptoms. 2. Consider referral to intensive counseling (multi-session, group or individual). Referral considerations include: • Multiple, unsuccessful quit attempts initiated by brief intervention. • Increased need for skill building (coping strategies/problem solving), social support and relapse prevention. • Psychiatric co-factor, such as depression, eating disorder, anxiety disorder, attention deficit (...) successful results on 150 mg/day. The appropriate total duration of bupropion has not been studied. Contraindications. Bupropion hydrochloride (Zyban ?) is contraindicated in patients with seizure disorder, past or present eating disorder, and in patients being treated with Wellbutrin ? or MAO inhibitors. To reduce seizure risk, the manufacturer recommends not exceeding maximum daily dose of 300 mg or single dose of 150 mg. Doses should be taken at least 8 hours apart. It should be used with caution

2012 University of Michigan Health System

114. Population Approaches to Improve Diet, Physical Activity, and Smoking Habits Full Text available with Trip Pro

Association Council on Epidemiology and Prevention, Council on Nutrition, Physical Activity and Metabolism, Council on Clinical Cardiology, Council on Cardiovascular Disease in the Young, Council on the Kidney in Cardiovascular Disease, Council on Peripheral Vascular Disease, and the Advocacy Coordinating Committee Originally published 20 Aug 2012 Circulation. 2012;126:1514–1563 You are viewing the most recent version of this article. Previous versions: Abstract Background— Poor lifestyle behaviors (...) habits, increase physical activity, and reduce tobacco use. Strategies were considered in 6 broad domains: (1) Media and educational campaigns; (2) labeling and consumer information; (3) taxation, subsidies, and other economic incentives; (4) school and workplace approaches; (5) local environmental changes; and (6) direct restrictions and mandates. The writing group also reviewed the potential contributions of healthcare systems and surveillance systems to behavior change efforts. Several specific

2012 American Heart Association

115. Atomoxetine PBPK-PD Clinical Study

: Undecided Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Product Manufactured in and Exported from the U.S.: No Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Atomoxetine Hydrochloride Adrenergic Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane (...) With Attention Deficit/Hyperactivity Disorder Actual Study Start Date : December 12, 2017 Estimated Primary Completion Date : June 30, 2022 Estimated Study Completion Date : June 30, 2022 Resource links provided by the National Library of Medicine available for: Groups and Cohorts Go to Intervention Details: Drug: Atomoxetine Hydrochloride Atomoxetine dose adjusted to achieve pre-defined concentration Outcome Measures Go to Primary Outcome Measures : Pharmacodynamic - metabolomic [ Time Frame: 18 weeks

2017 Clinical Trials

116. Platelet Rich Plasma (PRP) Peri-urethral and Clitoral Injections for the Treatment of Female Orgasmic Disorder

malignant disease. 〈 Who are not in a stable sexual relationship of at least 12 month duration 〈 Who suffer from systemic or generalized infections (bacterial, viral or fungal). 〈 Taking psychotropic medications including SSRIs, SNRIs, TCA, bupropion, mood stabilizers, & treatments for ADD or ADHD including Adderall and similar compounds. 〈 Taking sildenafil, vardenafil, tadalafil 〈 Taking topical or systemic estrogen or testosterone 〈 Taking oral contraceptive pills 〈 Who have been diagnosed (...) Platelet Rich Plasma (PRP) Peri-urethral and Clitoral Injections for the Treatment of Female Orgasmic Disorder Platelet Rich Plasma (PRP) Peri-urethral and Clitoral Injections for the Treatment of Female Orgasmic Disorder - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2017 Clinical Trials

117. IMProving Executive Function Study

undergoing RRSO (meaning they were having regular periods). They also must not have undergone radiation or chemotherapy in the past year. Furthermore, participants must not suffer from a mental illness, including Attention Deficit Hyperactivity Disorder (ADHD), and must not have a recent history of drug abuse. Additionally, participants must not suffer from a fear of small, enclosed spaces (claustrophobia), and not have any implanted medical devices such as a pacemaker, orthodontic braces, or shrapnel (...) : Lisdexamfetamine Stimulant medications are used to reduce interruptive behavior, fidgeting, and other hyperactive symptoms, as well as help a person finish tasks and improve his or her relationships for adults who have ADHD. Please note that the FDA has not approved the use of Vyvanse® for the treatment of memory and concentration difficulties related to medically induced menopause. Other Name: Vyvanse Placebo Comparator: Placebo Participants will have a 50% chance of receiving the placebo for this study

2017 Clinical Trials

118. Music to Reduce Use of Smoking in Patients With Schizophrenia

of Medicine Information provided by (Responsible Party): New York University School of Medicine Study Details Study Description Go to Brief Summary: The purpose of this study is to explore the impact of self-selected music listening which targets disrupting the reward process maintaining smoking and additionally attenuating the reward processing deficits associated with schizophrenia. Five participants with schizophrenia/schizoaffective disorder who smoke/nicotine will participate in an individual session (...) With Schizophrenia Actual Study Start Date : March 9, 2017 Estimated Primary Completion Date : July 1, 2021 Estimated Study Completion Date : July 1, 2022 Resource links provided by the National Library of Medicine related topics: related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Schizophrenia Patients Clinician verification diagnosis of Schizophrenia or Schizoaffective Disorder Behavioral: Music session Participants will be asked to refrain from smoking from 24 hours before

2017 Clinical Trials

119. Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years

Screening, Attention Deficit Hyperactivity Disorder, any Diagnostic and Statistical Manual of Mental Disorders, 5th Edition depressive disorder, bipolar disorder, or schizophrenia Known secondary causes (genetic, endocrine, or metabolic) for obesity (eg, Prader-Willi syndrome, Bardet Biedl syndrome, Down's Syndrome, untreated hypothyroidism, Cushing's syndrome, daily systemic corticosteroid exposure for longer than 30 days, history of significant exposure to corticosteroids for chronic illness during (...) × upper limit of normal (ULN), serum transaminases greater than 3× ULN, or total bilirubin greater than 1.5× ULN in absence of Gilbert's syndrome Any suicidal ideation with intent with or without a plan, at the time of or within 6 months of Screening, as indicated by answering "Yes" to questions 4 or 5 on the Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS) Any suicidal behavior in the past based on the C-SSRS Any history of anorexia or bulimia within 2 years before

2017 Clinical Trials

120. Effect of Galantamine on Inflammation and Cognition

): total score less than 8 (past 4 weeks), irritability, speech content, disruptive or aggressive behavior items score less than 3 (past 4 weeks) No psychiatric hospitalization or Emergency Room visits for psychiatric issues in the past 6 months No aggressive or violent acts or behavior in the past 6 months Able to communicate in English and provide written informed consent Will be residing in the geographic area for at least 7 months Not currently trying to quit smoking Smoking Status Smokers (HIV+S (...) of ernollment) Two or more lifetime suicide attempts or episodes of suicidal behavior Any suicide attempt or suicidal behavior within 2 years of enrollment Medication Current use or discontinuation within the last 14 days of: Quit smoking medications including varenicline (Chantix), bupropion (Wellbutrin) Anti-psychotic medications (e.g., Zyprexa, Clozaril, Seroquel, Risperdal). If used to treat psychotic symptoms. Other uses may be eligible pending physician approval). Systemic Steroids (e.g., Prednisone

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>